磺酰脲类降糖药物的临床药代动力学 - Suppr

Suppr

超能文献

Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs.

作者信息

Balant L

出版信息

Clin Pharmacokinet. 1981 May-Jun;6(3):215-41. doi: 10.2165/00003088-198106030-00003.

DOI:10.2165/00003088-198106030-00003

PMID:7016385

Abstract

摘要

相似文献

Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs.

Clin Pharmacokinet. 1981 May-Jun;6(3):215-41. doi: 10.2165/00003088-198106030-00003.

Pharmacokinetics of glipizide in man: influence of renal insufficiency.

Diabetologia. 1973 Sep:331-8. doi: 10.1007/BF01218443.

Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2.

Drugs. 1981 Oct;22(4):295-320. doi: 10.2165/00003495-198122040-00003.

[Pharmacokinetics of glibornuride].

Arzneimittelforschung. 1972 Dec;22:Suppl 12A:2209.

Pharmacokinetics and metabolism of 14C-glipentide, a new antidiabetic, after oral and intravenous administration.

Arzneimittelforschung. 1977;27(4):852-6.

[Potentiation of the hypoglycemic effect of sulfonylurea derivatives by drugs. II. Pharmacokinetics and metabolism of glibenclamide (HB 419) in presence of phenylbutazone].

Eur J Clin Pharmacol. 1971 Dec;4(1):32-7. doi: 10.1007/BF00568896.

[Influence of deficient kidney function on behavior of glipizide (hypoglycemic sulfonylurea) and its metabolites].

J Urol Nephrol (Paris). 1973 Apr-May;79(4):380-1.

Metabolism and kinetics of the hypoglycemic agent glipizide in man--comparison with glibenclamide.

J Clin Pharmacol New Drugs. 1973 Feb-Mar;13(2):68-75. doi: 10.1002/j.1552-4604.1973.tb00255.x.

[Pharmacokinetics of tolbutamide and glycodiazine in liver and kidney diseases].

Verh Dtsch Ges Inn Med. 1973;79:1220-3.

[Pharmacokinetics and metabolite spectrum of glisoxepide in humans].

Arzneimittelforschung. 1974 Mar;24(0):404-9.

引用本文的文献

Non-Alcoholic Fatty Liver Disease and Its Association With Diabetes Mellitus.

Cureus. 2021 Aug 20;13(8):e17321. doi: 10.7759/cureus.17321. eCollection 2021 Aug.

Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?

Pharmaceuticals (Basel). 2018 Nov 8;11(4):121. doi: 10.3390/ph11040121.

Hepatogenous Diabetes: An Underestimated Problem of Liver Cirrhosis.

Indian J Endocrinol Metab. 2018 Jul-Aug;22(4):552-559. doi: 10.4103/ijem.IJEM_79_18.

Sulfonylureas suppress the stimulatory action of Mg-nucleotides on Kir6.2/SUR1 but not Kir6.2/SUR2A KATP channels: a mechanistic study.

J Gen Physiol. 2014 Nov;144(5):469-86. doi: 10.1085/jgp.201411222.

Prediction of drug disposition in diabetic patients by means of a physiologically based pharmacokinetic model.

Clin Pharmacokinet. 2015 Feb;54(2):179-93. doi: 10.1007/s40262-014-0192-8.

[Cytochrom-P450 mediated drug interactions caused by antibiotics].

Wien Med Wochenschr. 2006 Sep;156(17-18):508-14. doi: 10.1007/s10354-006-0336-z.

Sulphonylurea drugs reduce hypoxic damage in the isolated perfused rat kidney.

Br J Pharmacol. 2000 Aug;130(7):1678-84. doi: 10.1038/sj.bjp.0703469.

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Clin Pharmacokinet. 1997 Mar;32(3):210-58. doi: 10.2165/00003088-199732030-00004.

Oral antidiabetic drug use in the elderly.

Drugs Aging. 1996 Dec;9(6):418-37. doi: 10.2165/00002512-199609060-00005.

Two types of potassium channel regulated by ATP in pancreatic B cells isolated from a type-2 diabetic human.

Pflugers Arch. 1993 May;423(3-4):265-73. doi: 10.1007/BF00374405.

本文引用的文献

Drug interactions and long-term antidiabetic therapy.

Br J Clin Pharmacol. 1976 Dec;3(6):1027-32. doi: 10.1111/j.1365-2125.1976.tb00353.x.

Influence of the absorption rate of tolbutamide on the rate of decline of blood sugar levels in normal humans.

J Pharm Sci. 1962 Jun;51:509-14. doi: 10.1002/jps.2600510603.

[INCREASE IN DRUG OXIDIZING ENZYME ACTIVITY WITH TOLBUTAMIDE].

Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1964 Oct 2;249:71-84. doi: 10.1007/BF00246370.

SERUM CONCENTRATION AND URINARY EXCRETION OF ORAL SULFONYLUREA COMPOUNDS: RELATION TO DIABETIC CONTROL.

Diabetes. 1965 Jun;14:362-7. doi: 10.2337/diab.14.6.362.

METABOLISM OF ANTIDIABETIC SULFONYLUREAS IN MAN. I. BIOLOGICAL HALF-LIVES OF THE P-ACETYLBENZENESULFONYLUREAS, U-18536 AND ACETOHEXAMIDE AND THEIR METABOLITES.

Metabolism. 1965 Mar;14:229-40. doi: 10.1016/0026-0495(65)90063-6.

RATE OF METABOLISM OF TOLBUTAMIDE IN TEST SUBJECTS WITH LIVER DISEASE OR WITH IMPAIRED RENAL FUNCTION.

Am J Med Sci. 1964 Dec;248:657-9. doi: 10.1097/00000441-196412000-00004.

SULPHAPHENAZOLE-INDUCED HYPOGLYCAEMIC ATTACKS IN TOLBUTAMIDE-TREATED DIABETICS.

Lancet. 1963 Dec 21;2(7321):1298-301. doi: 10.1016/s0140-6736(63)90847-x.

DISAPPEARANCE RATE OF TOLBUTAMIDE IN NORMAL SUBJECTS AND IN DIABETES MELLITUS, LIVER CIRRHOSIS, AND RENAL DISEASE.

Diabetes. 1963 Sep-Oct;12:414-9. doi: 10.2337/diab.12.5.414.

Protein interactions of sulfonylurea compounds.

Diabetes. 1962;11(Suppl):18-25.

A method for the routine determination of chlorpropamide in plasma.

Clin Chem. 1959 Dec;5:597-602.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验